Skip to content

ALRN-6924

Our Clinical Development Strategy to Deliver Selective Chemoprotection to Cancer Patients

We are implementing a clinical development strategy designed to maximize our opportunity to bring biomarker-driven, selective chemoprotection to all patients with p53-mutated cancer regardless of cancer type or chemotherapy.

About the Ongoing ALRN-6924 Breast Cancer Trial

Up to 75%
of patients receiving
TAC experience severe neutropenia
Up to 98%
of patients receiving
TAC experience
alopecia (hair loss)

*TAC=docetaxel, doxorubicin and cyclophosphamide chemotherapy regimen

ALRN-6924 Breast Cancer Trial Design

We are currently conducting a clinical trial of ALRN-6924 in patients with p53-mutated breast cancer. The Phase 1b, open-label, single-arm, multicenter trial is designed to evaluate the safety, tolerability and chemoprotective effect of ALRN-6924 in up to 24 patients with p53-mutated breast cancer undergoing either neoadjuvant or adjuvant treatment with docetaxel, doxorubicin and cyclophosphamide, a chemotherapy regimen also known as ‘TAC’.

The primary endpoints are duration and incidence of severe neutropenia (Grade 4) in cycle 1. Secondary endpoints include the chemoprotective effect of ALRN-6924 on chemotherapy-induced alopecia, as well as other hematologic and non-hematologic toxicities. TAC will be administered every 3 weeks for 4 to 6 cycles based on investigators’ discretion. ALRN-6924 will be administered at 1.2 mg/kg on 3 consecutive days in each treatment cycle, Days 0, 1 and 2, while chemotherapy will be administered on Day 1.

Upcoming Data Readouts

The planned readouts for the breast cancer trial include data from initial patients in 4Q 2022, an interim analysis on 12 patients in 2Q 2023, and topline results from 20 patients in 3Q 2023.

About Our Completed Small Cell Lung Cancer (SCLC) Trial

We presented final results from our completed Phase 1b trial in patients with p53-mutated SCLC receiving second-line topotecan at the European Society for Medical Oncology (ESMO) Congress 2021. Following the interim proof-of-concept data presented in October 2020 from this study, these final results reinforced ALRN-6924’s ‘triple-play’ reduction in neutropenia, thrombocytopenia and anemia caused by chemotherapy, as well as a reduction in febrile neutropenia, platelet transfusions and red blood cell transfusions.

View Poster

Mechanism of Action Data from Our Healthy Volunteer Study

We presented preliminary results from our Phase 1 pharmacology study of ALRN-6924 in healthy volunteers at the International Society for Experimental Hematology (ISEH) 2021 Scientific Meeting and ESMO 2021. These preliminary results demonstrated that a 1-hour infusion of ALRN-6924 was safe, well-tolerated, and transiently upregulated p21 in human bone marrow cells.

View Poster

As we reported in June 2022, new data generated from the Healthy Volunteer Study in 1H 2022 demonstrated that ALRN-6924 dose levels yielded longer-lasting pharmacodynamic (PD) effects. Specifically, the PD data demonstrated that serum levels of MIC-1 were correlated with bone marrow p21, which is a marker for cell cycle arrest. Based on these findings, we believe that prolonged elevation of serum levels of MIC-1 at higher ALRN-6924 dose levels may result in more durable cell cycle arrest.

We have submitted these and other new findings from the Healthy Volunteer Study for presentation at a scientific congress in 2H 2022.

 

Interested in partnering with Aileron?
Please contact us.